Back to today’s briefing

Story perspectives

States Push FDA to Relax Mifepristone Safety Standards

6/8/2025

49 5

Summary

Story summary

A coalition of states, including Massachusetts, California, New Jersey, and New York, is urging the FDA to relax safety standards for the abortion drug mifepristone. Proponents claim it is "extraordinarily safe," yet critics highlight rising complication rates compared to surgical options, raising serious concerns about women's health and the erosion of essential medical safeguards.

1 of 1

Story summary

A coalition of states, including Massachusetts, California, New Jersey, and New York, is urging the FDA to relax safety standards for the abortion drug mifepristone. Proponents claim it is "extraordinarily safe," yet critics highlight rising complication rates compared to surgical options, raising serious concerns about women's health and the erosion of essential medical safeguards.